
Opinion|Videos|July 23, 2024
Empowering Patients: Key Considerations for BTK Inhibitor Adherence
A conversation on how to empower patients and the considerations for BTK inhibitor adherence.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- What are the key considerations for educating and empowering patients about BTK inhibitors to support adherence for the course of long-term treatment?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5













































